Jaguar Health Subsidiary to Provide Crofelemer to Infant in EU for Compassionate Use

RegulatoryCrofelemerPositive

AI Analysis

Summary

Jaguar Health's subsidiary received approval to provide crofelemer to an infant patient in the EU under compassionate use provisions. This represents a routine regulatory approval for expanded access to the drug.

Outcome Details

Compassionate use approval for infant patient in EU

Importance:3/10

Sentiment:

0.30

compassionate_usecrofelemerEUpediatric

Related Companies

$JAGX

Read the original article

Published by yahoo_finance on July 22, 2026 1:43 PM

Read Original